Human rabies therapy: lessons learned from experimental studies in mouse models.

Area of Science:

• Neuroscience
• Virology
• Pharmacology

Background:

• Rabies is a fatal viral encephalitis.
• Ketamine has been anecdotally used in rabies survivors.
• Minocycline's neuroprotective properties prompted investigation.

Purpose of the Study:

• To evaluate ketamine's efficacy in a rabies mouse model.
• To assess minocycline's therapeutic potential in rabies.
• To determine the safety and effectiveness of these agents against rabies virus.

Main Methods:

• Ketamine and minocycline were tested in primary neuron cultures and in mouse models of rabies.
• Mice were infected with the CVS strain of rabies virus via intracerebral and peripheral routes.
• Therapeutic effects were assessed by clinical observation, mortality, and viral spread analysis.

Main Results:

• Ketamine demonstrated no significant therapeutic benefit in vitro or in vivo.
• Minocycline showed no benefit in neuron cultures.
• Minocycline aggravated neurological disease and increased mortality in mice, potentially by increasing viral spread and inflammation.

Conclusions:

• Ketamine is not recommended for widespread clinical use in rabies patients without further evidence.
• Minocycline should be avoided in rabies and viral encephalitis management due to adverse effects.
• Further research is needed to establish effective treatments for rabies.